Huntington disease (HD) is most prevalent among populations of western European descent and isolated populations where founder effects may operate. The aim of this study was to examine the epidemiology of HD in Cyprus, an island in southern Europe with extensive western European colonization in the past. All registered HD patients in the Cyprus, since 1994, were included. Detailed pedigrees and clinical information were recorded and maps, showing the geographic distribution of HD, were constructed. Requests for genetic testing were also examined. The project identified 58 clinically manifested cases of HD belonging to 19 families.
| INTRODUCTION
Huntington disease (HD) is a rare, chronic, autosomal dominant disorder causing progressive neurodegeneration in the central nervous system. 1 HD is the result of CAG trinucleotide repeats in the huntingtin (HTT) gene 2, 3 where expansions of 36 to 39 CAG repeats are of reduced penetrance, whereas expansions over 39 repeats show full penetrance, provided the carrier lives long enough. 4, 5 Individuals with 27 to 35 repeats are not at risk themselves, but their descendants can carry 40 or more repeats and develop HD. In fact, 10% to 15% of all HD cases arise from non-affected parents. 5 HD has a mean age of onset of approximately 40 years, and an average patient life expectancy after symptom onset of about 17 years. 6, 7 Adult-onset is the most common form of HD but early onset or juvenile HD (JHD), with age of onset before the age of 20, is also possible albeit rare. 6, 8 An inverse correlation has been evidenced between the repeat length of CAG expansion and the age at onset of HD. 5, 6 Age at onset also decreases in successive generations, a phenomenon termed "anticipation" which is due to CAG repeat instability especially in paternal transmission during which large intergenerational expansions can occur. 5 This occurs in more than 80% of meiotic transmissions in spermatogenesis, 8 thus, JHD cases are mostly paternal in origin. Increased CAG repeat lengths are also associated with worse disease severity. 9 Several studies on the HD prevalence have been published indicating that the prevalence of HD varies widely between different geographical regions. 10, 11 However, overall, western European countries and countries with populations of western European descent, such as the United States, Canada and Australia, display higher incidence and prevalence rates, while overall prevalence of the condition has increased over the past 50+ years. [10] [11] [12] [13] On the other hand, Asian populations display lower prevalence. 10, 11, 13 Incidence rates for HD in European countries vary from 0.11 to 0.8 cases per 100 000 population per year. 10, [12] [13] [14] [15] Similarly, HD prevalence estimations show variable prevalence rates for European populations, ranging from 0.5 to 12.0 cases per 100 000. [12] [13] [14] [15] This variation is partly explained by differences in diagnostic criteria and case ascertainment, and if pre-symptomatic cases are included, to the proportion of individuals opting to undergo predictive testing in the population. 10 Interestingly, observed HD clusters with higher than the average country prevalence, like around Lake Maracaibo in Venezuela, 16 could have resulted from founder effects and genetic drift, which can give rise to geographical clustering.
Cyprus displays geographical clusters with high prevalence of certain monogenic neurodegenerative diseases such as familial amyloid polyneuropathy in Kyrenia 17 and Friedreich's ataxia in Paphos. 18 Some of these clusters might have resulted from invasion and settlement of the island by numerous nations throughout its history. New genetic disorders were introduced to the population and either spread across the island in successive generations throughout the centuries 19 or clustered in specific geographical regions when the geographic spread was not extensive. However, a detailed epidemiological investigation of HD in Cyprus, which also examines the possibility of a founder effect, has not yet been carried out, and this is the aim of this study.
| MATERIAL AND METHODS

| Patients
The study and all procedures followed were approved by the Cyprus National Bioethics Committee. 
| Survival analysis
Disease duration was used to estimate the percentage of patients that died/survived at 5, 10, and 15 years after they were diagnosed.
The survival rate probability was calculated and presented graphically (using the non-parametric estimation of Kaplan-Meier) by type of HD, gender, age of onset, number of repeats in the mutant allele, and inheritance using the disease duration of affected deceased individuals. Cox-proportional hazards analysis was used to determine the effect of these variables on survival.
| Prevalence and incidence calculations
The prevalence and incidence of symptomatic HD were estimated based on the number of symptomatic patients and population census data from the Cyprus Statistical Service. 20 Total population numbers were used. For prevalence, the end-year population was used as the denominator and the number of alive symptomatic cases on 31 December of the respective year as the numerator. For incidence, the population at the beginning of the year was used in the denominator and the number of newly diagnosed cases throughout the year as the numerator.
| Estimation of potential carriers and heterozygotes in the population
The number of potential HTT mutation carriers in the population was roughly estimated using Coneally's 1:5 ratio, 21 which estimates 5 potential carriers for every 1 affected patient. The frequency and expected number of heterozygotes in the Cypriot population was roughly estimated based on the number of symptomatic patients in
Cyprus at the end of 2014 using the method described by Reed and Chandler. 22 This method assumes 100% case ascertainment of affected cases and does not account for reduced penetrance alleles in the HD population. 3 | RESULTS In addition, the number of CAG repeats in the diseased allele was strongly and significantly associated with age of onset, in an exponential manner (y = 220.11 e −0.037x
| Clinical characteristics
; Figure 1 ). However, disease duration was not associated with the number of repeats in deceased patients, when disease duration was log-transformed and entered into a linear regression model as a dependent variable (β = −0.01, 95% confidence interval, CI: −0.04, 0.01).
| Survival analysis
With respect to survival, the 5-, 10-, and 15-year survival probability from onset was 85.2%, 63.0% and 40.7%, respectively, with median disease duration of 13.0 years. As expected, JHD have a much shorter survival than adult onset cases (hazard ratio, HR: 9.56, 95%
CI: 1.87-48.84; Figure 2A ), and gender did not significantly influence survival ( Figure 2B ). However, subjects with an older age at onset seemed to have a less favorable survival (HR: 3.04, 95% CI: 1.12-8.26; Figure 2C ). Number of repeats of the pathologic allele and paternal or maternal inheritance were not found to be significantly associated with survival ( Figure 2D ,E). Survival results did not change after exclusion of JHD (n = 3) and/or suicide cases (n = 2) ( Figure S1 , Supporting information).
| Geographical clustering
All patients belonged to 1 of 19 families of which 16 were of Greek- 
| Incidence and prevalence
In 2015, the prevalence of manifest HD was 4.64 per 100 000 popu- 
| Diagnostic and predictive testing
The number of requests for genetic testing for the HTT mutation did not display a clear trend since 1994 ( Figure S2 ). As expected, there was a peak in requests in 1994 when the test became available and again in 2010 when several members of a large family were tested.
Moreover, there has not been an increase in predictive testing through the years.
Since 1994, a total of 229 tests were performed of which 50.2%
(n = 115) were diagnostic, 47.6% (n = 109) were predictive and 2.2% 
Age of Onset
Number of CAG Repeats in the Disease allele 
| Clinical and genetic anticipation
Anticipation results in parent-offspring pairs are illustrated in Figure S3A . Thirty four parent-offspring pairs were identified, however, genetic anticipation was not supported in these pairs (P = .5378). In fact, in maternal inheritance, the majority of parent-offspring pairs showed decreased rather than increased CAG repeats in the offspring. Looking at affected parent-offspring pairs (n = 15), however, clinical anticipation In 2015, the prevalence of manifest HD in Cyprus was 4.64 per 100 000 population and the incidence 0.12 per 100 000 population.
The crude annual incidence of symptomatic HD in Cyprus was comparable to other southern European countries, being similar to that of Greece (0.22-0.44 per 100 000 per year), 14 but higher than that of Italy (0.11 per 100 000 per year) 24 and lower than that of Spain (0.47 per 100 000 per year). 25 Furthermore, the frequency of symptomatic HD in Cyprus is similar to the frequency reported in the majority of published studies for western European countries, such as Italy, Spain, Germany, the Netherlands, France, Sweden and Poland. 10, 12, 14, 15 However, Cyprus' prevalence is higher than the prevalence reported in most studies on central and eastern European populations. 10 During the past 20 years there has been a steady increase in HD prevalence in Cyprus, despite negligible decrease in disease incidence.
Such a trend was also observed in Australia, North America, the United Kingdom and Western Europe. 10, 11 In the Cypriot population, this phenomenon may be explained by the hypothesis that as general population survival increases, longevity in HD patients is also likely to be favorably impacted or by the hypothesis that the more effective symptomatic treatments for HD may also have a positive effect on survival.
The similar prevalence rates with western European countries, lend support to the hypothesis of a founder effect in the Cypriot population during the colonization of the island from western European populations during the past millennium (more specifically 1191-1571 AD).
| Diagnostic and predictive testing
The observed increase in incidence and prevalence in 1994 highlights the importance of the availability of genetic testing for HD diagnosis and for more accurate calculation of incidence and prevalence rates.
However, genetic testing requests, together with the estimated numbers of potential carriers and heterozygotes in the population, highlight the reluctance of a fair proportion of the members of the known families in Cyprus to be genetically tested. Independently, these results also indicate that calculating the frequency of the mutation, using genetically confirmed cases, would lead to a gross underestimation.
Moreover, prenatal testing uptake is still very limited in this HD population probably because many patients were not aware of their carrier status at child-bearing age. Lastly, despite availability of the procedure, none of the families in this HD population opted for pre-implantation genetic diagnosis, probably due to the high cost of the procedure. 
| Geographical clustering
Year of Birth Number of CAG repeats
Spearman's rho = +0.31 P=0.0054
Scatterplot between the year of birth and the number of repeats in the mutant allele of patients (n = 58) Thirdly, all JHD cases were paternally inherited in our population in agreement with previous investigations 28, 29 and this is explained by the observation that paternally transmitted repeats are prone to large increases in size, in contrast to maternal transmission, where nearly equal numbers of expansions and contractions are seen, and the shifts are small. 28 After exclusion of JHD cases, 40.0% of cases were found to be paternally inherited and 56.4% were maternally inherited. These proportions are in agreement with Panas et al 14 who
| Clinical characteristics
studied HD in Greece. Paternally inherited HD was associated with earlier age at onset in this and other studies.
6,30
| Survival
With respect to survival, median survival in HD patients in Cyprus, excluding JHD and suicide cases, was 13.0 years, slightly lower than the survival observed in other countries. 7, 8, [30] [31] [32] The shorter disease duration in Cyprus may be due to an inaccuracy in identifying cases earlier than 1994 thus introducing bias in age of onset and thus disease duration estimates.
Survival analyses showed that juvenile onset cases have a much shorter survival than adult onset cases which was expected since JHD is associated with a larger number of repeats which in turn is associated with worse disease progression. 5, 9 Contrary to expectation subjects with a younger age at onset appeared to have a more favorable survival. This finding could be explained by reports that disease duration among late onset patients was shorter, leading to death earlier than early and early-middle onset patients. 8 Gender and CAG repeats did not influence survival as also evidenced in other studies. 31 Lastly, paternal or maternal inheritance did not show a significant association with survival in our study, contrary to one other study that showed shorter survival for males with paternally inherited disease. and begin with the settling of about 30 000 Turks who were given land once they arrived in Cyprus, following the Ottoman conquest of the island in 1571. 35 Additionally, many of the Turkish Cypriots were local
Christians who converted to Islam during the early years of Ottoman rule. 36 It is possible that none of the settlers or those converted was an HTT carrier, hence the lack of HD among Turkish Cypriots.
| Perspectives
This investigation is the first of its kind in Cyprus, providing reliable estimates to the health care professionals and stakeholders on the island. This study included only genetically and clinically HD confirmed cases at CING and case ascertainment for symptomatic HD has been very high given that CING is the only tertiary neurology center on the island, specializing in neuromuscular disorders. Another strength of this study is the high quality of information collected since personal interviews with the patients and information from medical records were employed. Therefore, this study encourages further investigation as to whether the Cypriot families with HD positive history are actually unlinked and whether the one sporadic case is a result of genetic drift or is somehow linked to an already existing HD family. HTT haplotype analysis and genetic genealogy through autosomal DNA analysis could be valuable towards this endeavor.
| CONCLUSION
In Cyprus, HD disease characteristics, incidence and prevalence were comparable to western European populations. Taken together with the geographical clustering of HD families observed, these results support the possibility for a founder effect and suggest a western
European origin of HD in Cyprus.
